{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:42:40Z","timestamp":1787506960222,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nonalcoholic steatohepatitis (NASH) is the most severe and progressive form of nonalcoholic fatty liver disease (NAFLD), which can lead to life-threatening conditions, however, there is still no approved drug for the treatment of NASH. In this study we used human-like NASH mouse model and treated orally with isorhamnetin at a dose of 50\u2009mg\/kg to analyze the effect of isorhamnetin on the progression of NASH. NASH-induced mice represented severe steatosis with inflammation, and fibrosis in liver accompanied with high level of liver injury markers in serum. Isorhamnetin treatment reduced intrahepatic lipid accumulation and TG content by inhibiting\n                    <jats:italic>de novo<\/jats:italic>\n                    lipogenic pathway in NASH-induced mice. Consistent with this, isorhamnetin-treated NASH mice showed improved liver injury markers, reduced collagen deposition as well as decreased gene expression of fibrogenic markers. Taken together, here we showed for the first time that synthesized isorhamnetin alleviates pathologic features of NASH and thus can potentially contribute to NASH drug development.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-52736-y","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T06:05:29Z","timestamp":1573106729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis"],"prefix":"10.1038","volume":"9","author":[{"given":"Munkhzul","family":"Ganbold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Owada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Ferdousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-3190","authenticated-orcid":false,"given":"Yun-Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Ohkohchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"52736_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"52736_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/liv.13637","volume":"38","author":"L Serfaty","year":"2018","unstructured":"Serfaty, L. Management of patients with non-alcoholic steatohepatitis (NASH) in real life. Liver Int. 38, 52\u201355 (2018).","journal-title":"Liver Int."},{"key":"52736_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1053\/j.gastro.2016.02.044","volume":"150","author":"AJ Sanyal","year":"2016","unstructured":"Sanyal, A. J. & Miller, V. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis. Gastroenterology 150, 1723\u20131727 (2016).","journal-title":"Gastroenterology"},{"key":"52736_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/labinvest.3700489","volume":"87","author":"IA Leclercq","year":"2007","unstructured":"Leclercq, I. A., Lebrun, V. A., St\u00e4rkel, P. & Horsmans, Y. J. Intrahepatic insulin resistance in a murine model of steatohepatitis: Effect of PPAR\u03b3 agonist pioglitazone. Lab. Investig. 87, 56\u201365 (2007).","journal-title":"Lab. Investig."},{"key":"52736_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3727\/105221617X15093707969658","volume":"18","author":"K Stephenson","year":"2018","unstructured":"Stephenson, K. et al. Updates on dietary models of nonalcoholic fatty liver disease: Current studies and insights. Gene Expr. 18, 5\u201317 (2018).","journal-title":"Gene Expr."},{"key":"52736_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/1440-1681.12102","volume":"40","author":"N Kubota","year":"2013","unstructured":"Kubota, N. et al. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice. Clin. Exp. Pharmacol. Physiol. 40, 422\u2013430 (2013).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"52736_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","volume":"69","author":"T Tsuchida","year":"2018","unstructured":"Tsuchida, T. et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J. Hepatol. 69, 385\u2013395 (2018).","journal-title":"J. Hepatol."},{"key":"52736_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/pin.12612","volume":"68","author":"Y Owada","year":"2018","unstructured":"Owada, Y. et al. Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features. Pathol. Int. 68, 12\u201322 (2018).","journal-title":"Pathol. Int."},{"key":"52736_CR9","doi-asserted-by":"crossref","unstructured":"Hossain, M. K. et al. Molecular mechanisms of the anti-obesity and anti-diabetic properties of flavonoids. Int. J. Mol. Sci. 17 (2016).","DOI":"10.3390\/ijms17040569"},{"key":"52736_CR10","doi-asserted-by":"crossref","unstructured":"Vinayagam, R. & Xu, B. Antidiabetic properties of dietary flavonoids: A cellular mechanism review. Nutr. Metab. 12 (2015).","DOI":"10.1186\/s12986-015-0057-7"},{"key":"52736_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.fitote.2011.01.018","volume":"82","author":"D Proch\u00e1zkov\u00e1","year":"2011","unstructured":"Proch\u00e1zkov\u00e1, D., Bou\u0161ov\u00e1, I. & Wilhelmov\u00e1, N. Antioxidant and prooxidant properties of flavonoids. Fitoterapia 82, 513\u2013523 (2011).","journal-title":"Fitoterapia"},{"key":"52736_CR12","doi-asserted-by":"publisher","first-page":"6745","DOI":"10.3892\/mmr.2015.4269","volume":"12","author":"S Hu","year":"2015","unstructured":"Hu, S. et al. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen-activated protein kinase kinase signaling pathways. Mol. Med. Rep. 12, 6745\u20136751 (2015).","journal-title":"Mol. Med. Rep."},{"key":"52736_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.canlet.2008.05.040","volume":"270","author":"HJ Lee","year":"2008","unstructured":"Lee, H. J. et al. Mitochondria-cytochrome C-caspase-9 cascade mediates isorhamnetin-induced apoptosis. Cancer Lett. 270, 342\u2013353 (2008).","journal-title":"Cancer Lett."},{"key":"52736_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.taap.2013.10.026","volume":"274","author":"JH Yang","year":"2014","unstructured":"Yang, J. H. et al. Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol. Appl. Pharmacol. 274, 293\u2013301 (2014).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"52736_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jnutbio.2014.04.006","volume":"25","author":"W Dou","year":"2014","unstructured":"Dou, W. et al. Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. J. Nutr. Biochem. 25, 923\u2013933 (2014).","journal-title":"J. Nutr. Biochem."},{"key":"52736_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/oby.2008.472","volume":"17","author":"J Lee","year":"2009","unstructured":"Lee, J. et al. Isorhamnetin represses adipogenesis in 3T3-L1 cells. Obes. (Silver Spring) 17, 226\u2013232 (2009).","journal-title":"Obes. (Silver Spring)"},{"key":"52736_CR17","doi-asserted-by":"publisher","first-page":"368658","DOI":"10.1155\/2013\/368658","volume":"2013","author":"F Zar Kalai","year":"2013","unstructured":"Zar Kalai, F. et al. Antiobesity effects of an edible halophyte Nitraria retusa Forssk in 3T3-L1 preadipocyte differentiation and in C57B6J\/L mice fed a high fat diet-induced obesity. Evidence-based Complement. Altern. Med. 2013, 368658 (2013).","journal-title":"Evidence-based Complement. Altern. Med."},{"key":"52736_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.fct.2014.07.029","volume":"72","author":"F Zar Kalai","year":"2014","unstructured":"Zar Kalai, F., Han, J., Ksouri, R., Abdelly, C. & Isoda, H. Oral administration of Nitraria retusa ethanolic extract enhances hepatic lipid metabolism in db\/db mice model \u2018BKS.Cg-Dock7m+\/+ Leprdb\/J\u2019 through the modulation of lipogenesis-lipolysis balance. Food Chem. Toxicol. 72, 247\u2013256 (2014).","journal-title":"Food Chem. Toxicol."},{"key":"52736_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejphar.2016.04.042","volume":"783","author":"JH Yang","year":"2016","unstructured":"Yang, J. H. et al. Isorhamnetin attenuates liver fibrosis by inhibiting TGF-\u03b2\/Smad signaling and relieving oxidative stress. Eur. J. Pharmacol. 783, 92\u2013102 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"52736_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09673-5","volume":"7","author":"L Wu","year":"2017","unstructured":"Wu, L. et al. Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-\u03b21\/Smads and PI3K\/Akt pathways. Sci. Rep. 7, 9289 (2017).","journal-title":"Sci. Rep."},{"key":"52736_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/bcpt.12049","volume":"112","author":"\u00c9 Marcolin","year":"2013","unstructured":"Marcolin, \u00c9. et al. Quercetin Decreases Liver Damage in Mice with Non-Alcoholic Steatohepatitis. Basic Clin. Pharmacol. Toxicol. 112, 385\u2013391 (2013).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"12","key":"52736_CR22","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1021\/jf101192k","volume":"58","author":"Lifeng Zhang","year":"2010","unstructured":"Zhang, L. et al. Quercetin aglycone is bioavailable in murine pancreas and pancreatic xenografts. J. Agric. Food Chem., https:\/\/doi.org\/10.1021\/jf101192k (2010).","journal-title":"Journal of Agricultural and Food Chemistry"},{"key":"52736_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.fitote.2011.10.012","volume":"83","author":"G Li","year":"2012","unstructured":"Li, G. et al. Pharmacokinetic properties of isorhamnetin, kaempferol and quercetin after oral gavage of total flavones of Hippophae rhamnoides L. in rats using a UPLC-MS method. Fitoterapia 83, 182\u2013191 (2012).","journal-title":"Fitoterapia"},{"key":"52736_CR24","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1002\/jsfa.5697","volume":"92","author":"F Perez-Vizcaino","year":"2012","unstructured":"Perez-Vizcaino, F., Duarte, J. & Santos-Buelga, C. The flavonoid paradox: Conjugation and deconjugation as key steps for the biological activity of flavonoids. J. Sci. Food Agric. 92, 1822\u20131825 (2012).","journal-title":"J. Sci. Food Agric."},{"key":"52736_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.26698","volume":"59","author":"L Yang","year":"2014","unstructured":"Yang, L. et al. TGF-\u03b2 signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism. Hepatology 59, 483\u2013495 (2014).","journal-title":"Hepatology"},{"key":"52736_CR26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0016-5085(03)00907-7","volume":"125","author":"AE Feldstein","year":"2003","unstructured":"Feldstein, A. E. et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437\u2013443 (2003).","journal-title":"Gastroenterology"},{"key":"52736_CR27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly, K. L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343\u20131351 (2005).","journal-title":"J. Clin. Invest."},{"key":"52736_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1172\/JCI34275","volume":"118","author":"C Postic","year":"2008","unstructured":"Postic, C. & Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest. 118, 829\u2013838 (2008).","journal-title":"J. Clin. Invest."},{"key":"52736_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125\u20131131 (2002).","journal-title":"J. Clin. Invest."},{"key":"52736_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.redox.2015.08.015","volume":"6","author":"K Richter","year":"2015","unstructured":"Richter, K., Konzack, A., Pihlajaniemi, T., Heljasvaara, R. & Kietzmann, T. Redox-fibrosis: Impact of TGF\u03b21 on ROS generators, mediators and functional consequences. Redox Biol. 6, 344\u2013352 (2015).","journal-title":"Redox Biol."},{"key":"52736_CR31","first-page":"160","volume":"15","author":"J Arauz","year":"2016","unstructured":"Arauz, J., Ramos-Tovar, E. & Muriel, P. Redox state and methods to evaluate oxidative stress in liver damage: From bench to bedside. Ann. Hepatol. 15, 160\u2013173 (2016).","journal-title":"Ann. Hepatol."},{"key":"52736_CR32","first-page":"1","volume":"3 JUL","author":"Z Bian","year":"2012","unstructured":"Bian, Z. & Ma, X. Liver fibrogenesis in non-alcoholic steatohepatitis. Front. Physiol. 3 JUL, 1\u20137 (2012).","journal-title":"Front. Physiol."},{"key":"52736_CR33","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3748\/wjg.v24.i16.1679","volume":"24","author":"E Hern\u00e1ndez-Aquino","year":"2018","unstructured":"Hern\u00e1ndez-Aquino, E. & Muriel, P. Beneficial effects of naringenin in liver diseases: Molecular mechanisms. World J. Gastroenterol. 24, 1679\u20131707 (2018).","journal-title":"World J. Gastroenterol."},{"key":"52736_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-016-0392-3","volume":"16","author":"Z Chen","year":"2017","unstructured":"Chen, Z., Yu, R., Xiong, Y., Du, F. & Zhu, S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 16, 1\u20139 (2017).","journal-title":"Lipids Health Dis."},{"key":"52736_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.metabol.2017.04.011","volume":"72","author":"I Reccia","year":"2017","unstructured":"Reccia, I. et al. Non-alcoholic Fatty Liver Disease: A sign of systemic disease. Metabolism. 72, 94\u2013108 (2017).","journal-title":"Metabolism."},{"key":"52736_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","volume":"29","author":"F Diraison","year":"2003","unstructured":"Diraison, F., Moulin, P. & Beylot, M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 29, 478\u2013485 (2003).","journal-title":"Diabetes Metab."},{"key":"52736_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.metabol.2014.04.003","volume":"63","author":"F Ameer","year":"2014","unstructured":"Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H. & Zaidi, N. De novo lipogenesis in health and disease. Metabolism 63, 895\u2013902 (2014).","journal-title":"Metabolism"},{"key":"52736_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","volume":"146","author":"JE Lambert","year":"2014","unstructured":"Lambert, J. E., Roman, M. A. R., Browning, J. D. & Parks, E. J. Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease. Gastroenterology 146, 726\u2013735 (2014).","journal-title":"Gastroenterology"},{"key":"52736_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2010.01275.x","volume":"12","author":"P. Ferr\u00e9","year":"2010","unstructured":"Ferr\u00e9, P. & Foufelle, F. Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes, Obes. Metab., https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01275.x (2010).","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"52736_CR40","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt, E. M. et al. The NAS and the Histophatologic Diagnosis of NAFLD: Distinct Clinicopathologic Meanings. Hepatology 53, 810\u2013820 (2011).","journal-title":"Hepatology"},{"key":"52736_CR41","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1053\/jhep.2002.32527","volume":"35","author":"M Charlton","year":"2002","unstructured":"Charlton, M., Sreekumar, R., Rasmussen, D., Lindor, K. & Nair, K. S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 35, 898\u2013904 (2002).","journal-title":"Hepatology"},{"key":"52736_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/srep19288","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Dietary component isorhamnetin is a PPAR\u03b3 antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. Sci. Rep. 6, 19288 (2016).","journal-title":"Sci. Rep."},{"key":"52736_CR43","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1039\/C4FO01092B","volume":"6","author":"C Rodr\u00edguez-Rodr\u00edguez","year":"2015","unstructured":"Rodr\u00edguez-Rodr\u00edguez, C. et al. The effect of isorhamnetin glycosides extracted from Opuntia ficus-indica in a mouse model of diet induced obesity. Food Funct. 6, 805\u2013815 (2015).","journal-title":"Food Funct."},{"key":"52736_CR44","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1021\/jf0202133","volume":"50","author":"T Yokozawa","year":"2002","unstructured":"Yokozawa, T., Kim, H. Y., Cho, E. J., Choi, J. S. & Chung, H. Y. Antioxidant effects of isorhamnetin 3,7-di-O-\u03b2-D-glucopyranoside isolated from mustard leaf (Brassica juncea) in rats with streptozotocin-induced diabetes. J. Agric. Food Chem. 50, 5490\u20135495 (2002).","journal-title":"J. Agric. Food Chem."},{"key":"52736_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bpg.2011.02.005","volume":"25","author":"UE Lee","year":"2011","unstructured":"Lee, U. E. & Friedman, S. L. Mechanisms of Hepatic Fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 25, 195\u2013206 (2011).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"52736_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/648915","volume":"2012","author":"JB Chakraborty","year":"2012","unstructured":"Chakraborty, J. B., Oakley, F. & Walsh, M. J. Mechanisms and Biomarkers of Apoptosis in Liver Disease and Fibrosis. Int. J. Hepatol. 2012, 1\u201310 (2012).","journal-title":"Int. J. Hepatol."},{"key":"52736_CR47","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1021\/acs.jnatprod.6b00274","volume":"79","author":"K Kato","year":"2016","unstructured":"Kato, K., Ninomiya, M., Tanaka, K. & Koketsu, M. Effects of Functional Groups and Sugar Composition of Quercetin Derivatives on Their Radical Scavenging Properties. J. Nat. Prod. 79, 1808\u20131814 (2016).","journal-title":"J. Nat. Prod."},{"key":"52736_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17370-6","volume":"7","author":"S Cazanave","year":"2017","unstructured":"Cazanave, S. et al. The Transcriptomic Signature of Disease Development and Progression of Nonalcoholic Fatty Liver Disease. Sci. Rep. 7, 1\u201313 (2017).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52736-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52736-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52736-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:31:18Z","timestamp":1671273078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-52736-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["52736"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-52736-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"8 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16210"}}